GSK, Pfizer merger won’t cause Nurofen maker any pain, ACCC says
Competition & Consumer Protection 2019-05-09 8:24 pm Sydney
The Australian Competition and Consumer Commission has signed off on pharmaceutical giant GlaxoSmithKline’s proposed acquisition of fellow heavyweight Pfizer, a merger which will put pain medications Panadol, Voltaren and Advil all under one roof, with the competition cop saying Nurofen maker Reckitt will still be able to compete.